P
CPRX

Paradiem’s Catalyst Pharmaceutical CPRX Stock Holding History

Paradiem’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-181,295
Closed -$2.89M – 94
2024
Q1 		$2.89M Sell
181,295
-16,924
-9% -$255K 0.71% 60
2023
Q4 		$3.33M Buy
198,219
+31,314
+19% +$428K 0.93% 51
2023
Q3 		$1.95M Sell
166,905
-75,516
-31% -$1.01M 0.59% 72
2023
Q2 		$3.26M Buy
242,421
+5,793
+2% +$83.4K 0.93% 58
2023
Q1 		$3.92M Buy
+236,628
New +$3.9M 1.22% 38

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paradiem's CPRX Position: Q2 2024 in Review

Paradiem sold out of Catalyst Pharmaceutical (CPRX) in Q2 2024, closing a stake of 181,295 shares — an estimated $2.89M sold.

Paradiem first reported a position in CPRX in Q1 2023 and held it in 5 quarters. The position peaked at $3.92M in Q1 2023. 271 funds tracked by Wall St. Rank hold CPRX as of Q2 2024.

  • Paradiem reported no remaining Catalyst Pharmaceutical position as of Q2 2024 after selling out during the quarter.
  • Paradiem sold 181,295 Catalyst Pharmaceutical shares in Q2 2024, an estimated $2.89M.
  • Paradiem first reported a position in Catalyst Pharmaceutical in Q1 2023 and held it in 5 quarters.
  • Paradiem's Catalyst Pharmaceutical position peaked at $3.92M in Q1 2023.
  • 271 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2024.

Based on Paradiem's 13F filing for Q2 2024, filed 22 Jul 2024.